ReviewHPB : the official journal of the International Hepato Pancreato Biliary Association2012
Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature.
Review in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05172310 (PET Imaging of Tumors in Pancreas, Bile Ducts, Stomach and Ovaries by a Novel Tracer, 68Ga-FAPI-46 = Fibroblast Activation Protein Inhibitor), which is not on this map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PET Imaging of Tumors in Pancreas, Bile Ducts, Stomach and Ovaries by a Novel Tracer, 68Ga-FAPI-46 = Fibroblast Activation Protein Inhibitor
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- Misdiagnosis of Suspected Cancer in Pancreatoduodenectomy: A Systematic Review and Prevalence Mata-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Current and future intraoperative imaging strategies to increase radical resection rates in pancreatic cancer surgery.BioMed research international · 2014Pooled it
- Clinical and imaging differences between pancreatic carcinoma in situ and T1a/T1b pancreatic ductal adenocarcinoma.Abdominal radiology (New York) · 2026Article
- Pancreatic Cancer-Advances in the Last 50 Years.World journal of surgery · 2026Review
- Diagnostic utility of endoscopic ultrasound features in pancreatic tumors: a retrospective observational study focusing on tumor size and imaging characteristics.BMC gastroenterology · 2026Observational
- Live and learn: unexpected benign disease after pancreaticoduodenectomy for presumed malignancy.Updates in surgery · 2026Article
- Small pancreatic ductal adenocarcinoma (≤ 2 cm): different imaging and clinicopathologic features according to extrapancreatic extension.Abdominal radiology (New York) · 2025Article
- Radiological Assessment After Pancreaticoduodenectomy for a Precision Approach to Managing Complications: A Narrative Review.Journal of personalized medicine · 2025Review
- Article
- An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment.The British journal of radiology · 2025Review
- Imaging Techniques and Biochemical Biomarkers: New Insights into Diagnosis of Pancreatic Cancer.Cell biochemistry and biophysics · 2024Review
- Review
- Prognostic Impact of Para-Aortic Lymph Node Metastasis in Resected Non-Pancreatic Periampullary Cancers.Annals of surgical oncology · 2024Article
- Role of Endoscopic Ultrasound in Pancreatic Cancer Diagnosis and Management.Diagnostics (Basel, Switzerland) · 2024Review
- A narrative review of imaging for pancreas adenocarcinoma: staging, surgical considerations, and surveillance.Journal of gastrointestinal oncology · 2023Review
- Pancreatic Cancer and Detection Methods.Biomedicines · 2023Review
- Article
- Utility of interventional endoscopic ultrasound in pancreatic cancer.Frontiers in oncology · 2023Review
- Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer.Cancers · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate pre-operative imaging in pancreatic cancer helps avoid unsuccessful surgical explorations and forewarns surgeons regarding aberrant anatomy. This review aimed to determine the role of current imaging modalities in the diagnosis and determination of resectability of pancreatic and peri-ampullary adenocarcinomas.
methodsA systematic search of the scientific literature was carried out using EMBASE, PubMed/MEDLINE and the Cochrane Central Register of Controlled Trials for the years 1990 to 2011 to obtain access to all publications, especially randomized controlled trials, reporting on the diagnostic accuracy of ultrasonography, multi-detector computed tomography (MDCT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS) or positron emission tomography (PET)-computed tomography (CT) and the evaluation of resectability of pancreatic and peri-ampullary adenocarcinomas.
resultsBased on 66 articles analysed in the review, MDCT and MRI/MRCP have comparable sensitivity and specificity rates for diagnosis and staging of pancreatic cancers. EUS offers the best sensitivity and specificity rates for lesions <2 cm. Improved staging has been noted when PET-CT scans are added to pre-operative evaluation.
conclusionsMDCT with angiography or MRI/MRCP should constitute the first imaging modality in suspected pancreatic adenocarcinomas. EUS is recommended for assessing lesions not clearly detected, but suspected, on CT/MRI and in tumours considered 'borderline resectable' on MDCT to assess vascular involvement. PET-CT in locally advanced lesions will help rule out distant metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.